Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan 2;135(1):71-75.
doi: 10.1182/blood.2019003407.

Predicting success of desensitization after pegaspargase allergy

Hope D Swanson  1 , John C Panetta  1 , Patricia J Barker  1 , Yiwei Liu  1 , Hiroto Inaba  1 , Mary V Relling  1 , Ching-Hon Pui  1 , Seth E Karol  1
Affiliations

Predicting success of desensitization after pegaspargase allergy

Hope D Swanson et al. Blood. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Antibody status influences day 14 asparaginase activity after desensitization. Estimated day 14 activity based on a 2500 IU/m2 dose of PEG-ASP subdivided by antibody status before desensitization. The boxes represent the median and interquartile range, and the whiskers represent the range. Individual patient activity estimates are indicated with dots.
See this image and copyright information in PMC

References

    1. Henriksen LT, Harila-Saari A, Ruud E, et al. ; Nordic Society of Paediatric Haematology and Oncology (NOPHO) group . PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol. Pediatr Blood Cancer. 2015;62(3):427-433. - PubMed
    1. Browne EK, Moore C, Sykes A, Lu Z, Jeha S, Mandrell BN. Clinical characteristics of intravenous PEG-asparaginase hypersensitivity reactions in patients undergoing treatment for acute lymphoblastic leukemia. J Pediatr Oncol Nurs. 2018;35(2):103-109. - PMC - PubMed
    1. Liu Y, Smith CA, Panetta JC, et al. . Antibodies predict pegaspargase allergic reactions and failure of rechallenge. J Clin Oncol. 2019;37(23):2051-2061. - PMC - PubMed
    1. Stock W, Luger SM, Advani AS, et al. . A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019;133(14):1548-1559. - PMC - PubMed
    1. Cooper SL, Young DJ, Bowen CJ, Arwood NM, Poggi SG, Brown PA. Universal premedication and therapeutic drug monitoring for asparaginase-based therapy prevents infusion-associated acute adverse events and drug substitutions. Pediatr Blood Cancer. 2019;66(8):e27797. - PMC - PubMed

Publication types

MeSH terms